Recently, Beijing Municipal Commission of Development and Reform officially released the Catalog of Beijing’s 2025 First Batch of First Units (Sets) of Major Technical Equipment. AccuMedical’s Lattice NEXT Flow Diverter was successfully selected for inclusion.
To be included in the catalog, products must undergo a rigorous process, including formal review, expert evaluation, on-site verification, deliberation by the Expert Advisory Committee, joint departmental review, and final approval by the municipal government. Selected products must demonstrate significant technological breakthroughs, play a key role in the industrial value chain, and have a strong driving force for industrial development. Lattice NEXT’s inclusion in the "Pharmaceutical and Healthcare - Medical Devices - Passive Implantable Devices" the Catalog of Beijing’s 2025 First Batch of First Units (Sets) of Major Technical Equipment (Pharmaceutical and Healthcare and Other Fields) represents a high-level recognition of its advanced technology and market value.
AccuMedical’s Lattice NEXT features an innovative “non-extended” guidewire tip design and an optimized stent delivery system, enabling smoother navigation and more controlled deployment, particularly in complex intracranial aneurysm cases involving tortuous vessels. With its groundbreaking technological innovations, both the Lattice and Lattice NEXT significantly reduce the complexity of surgical operations, shorten procedure times, improve patient outcomes, and enhance surgical safety — marking a new era of “automatic mode” in intracranial aneurysm treatment. The devices have already been adopted and used in multiple hospitals, receiving widespread acclaim from clinicians. As the difficulty of procedures is reduced, these treatments are becoming more accessible to remote and county-level hospitals, empowering younger physicians to perform aneurysm procedures with this stent and truly meeting urgent clinical needs.
Since its founding, AccuMedical has regarded technological innovation as its core competitiveness. To date, nine products including Lattice and Lattice NEXT have been approved by the NMPA. The company has filed 132 patent applications, of which 73 have been granted. AccuMedical was recognized as a National High-Tech Enterprise in 2023 and as a National-level “Little Giant” Enterprise in 2024. Moving forward, AccuMedical will take this honor as a new starting point to continue its innovation in the field of neurointervention and to contribute to the protection of human health.